Drugs / Levo Praziquantel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02806232 | Jun 2016 → Oct 2018 | Schistosoma mansoni infectious disease | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levo Praziquantel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02806232 ↗ |
| Route | Oral | “Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.” NCT02806232 ↗ |